FXR agonists such as OCA and cilofexor, as well as aldafermin and ASBTi, are already extensively studied as monotherapy or in combination with UDCA in phase II and III clinical trials for various cholestatic liver diseases.5 This evidence concerns the gene NR1H4 and Cholestatic liver disease.